Medical specialists from Japan tagged as investigators in clinical trials studying Hepatitis A

Total 18 results

Atsumasa Komori
Seen in:
- Nagasaki, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Jun Hayashi
Seen in:
- Fukuoka, Department of General Medicine, Kyushu University Hospital
Trials:
- NCT00956982 (Principal Investigator)
Conditions:
- Hepatitis C Virus
Kazuo Notsumata
Seen in:
- Fukui, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Ken Furuya
Seen in:
- Hokkaido, GSK Investigational Site
- Hokkaido, Sapporo-shi, JCHO Hokkaido Hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05630820 (Principal Investigator)
Conditions:
Masanori Atsukawa
Seen in:
- Tokyo, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Nami Mori
Seen in:
- Hiroshima, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Naoya Sakamoto
Seen in:
- Hokkaido, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
Conditions:
- Chronic Hepatitis B;
- Hepatitis B, Chronic
Satoyoshi Yamashita
Seen in:
- Yamaguchi, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
Conditions:
- Chronic Hepatitis B;
- Hepatitis B, Chronic
Shigetoshi Fujiyama
Seen in:
- Kumamoto, GSK Investigational Site
- Kumamoto, Kumamoto Shinto General Hospital
Trials:
- NCT05630807 (Principal Investigator)
- NCT04166773 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Shinya Minami
Seen in:
- Hokkaido, GSK Investigational Site
Trials:
- NCT05630807 (Principal Investigator)
Conditions:
- Chronic Hepatitis B
Tadashi Namisaki
Seen in:
- Nara, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
Conditions:
Takeshi Matsui
Seen in:
- Hokkaido, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
Conditions:
- Chronic Hepatitis B;
- Hepatitis B, Chronic
Takuya Komura
Seen in:
- Ishikawa, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Takuya Nagano
Seen in:
- Kagawa, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Tetsuo Takehara
Seen in:
- Osaka, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Toru Ishikawa
Seen in:
- Niigata, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
Conditions:
- Chronic Hepatitis B;
- Hepatitis B, Chronic
Yasuhito Tanaka
Seen in:
- Kumamoto, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Yuichiro Suzuki
Seen in:
- Yamanashi, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:

Clinical Trials on Hepatitis A

Boryung Pharmaceutical Co., Ltd

Completed

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-C)

Hepatitis A Vaccine

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents

Hepatitis A | Hepatitis A Virus

China
Boryung Pharmaceutical Co., Ltd

Completed

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)

Hepatitis A Vaccine

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)

Hepatitis A Virus Infection
GlaxoSmithKline

Completed

This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama

Hepatitis A Vaccine

Panama
GlaxoSmithKline

Completed

Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children

Hepatitis | Acute Hepatitis A

Panama
Grifols Therapeutics LLC

Completed

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) (GamaSTAN)

Anti-Hepatitis A Antibody Levels in Heathy Subjects

United States
Boryung Biopharma Co., Ltd.

Not yet recruiting

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs

Hepatitis A | Hep A

Korea, Republic of, Thailand
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

Hepatitis A Virus
University of Maryland, Baltimore
Alexandria University; MADAUS GmbH; The Egyptian Company for Blood Transfusion... and other collaborators

Terminated

Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

Acute Hepatitis C | Acute Hepatitis B | Acute Hepatitis A | Acute Hepatitis E | Acute EBV Hepatitis | Acute CMV Hepatitis

Egypt

Medical specialists from Japan tagged as investigators in clinical trials studying Hepatitis A

Clinical Trials on Hepatitis A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations